JPH11504515A - ウトロフィン遺伝子プロモーター - Google Patents
ウトロフィン遺伝子プロモーターInfo
- Publication number
- JPH11504515A JPH11504515A JP8532261A JP53226196A JPH11504515A JP H11504515 A JPH11504515 A JP H11504515A JP 8532261 A JP8532261 A JP 8532261A JP 53226196 A JP53226196 A JP 53226196A JP H11504515 A JPH11504515 A JP H11504515A
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- nucleic acid
- sequence
- isolate
- utrophin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ウトロフィン遺伝子プロモーターを含んで成る、核酸単離物。 2.核酸単離物であって、(i)図2に示されたプロモーターのヌクレオチド の配列及び(ii)図5に示されたマウスのプロモーター配列のヌクレオチドの配 列から選択するヌクレオチドの配列を含むプロモーターを含んで成る、前記単離 物。 3.核酸単離物であって、図2の5′から位置 898に示されたヌクレオチドの 配列を含むプロモーターを含んで成る、前記単離物。 4.核酸単離物であって、図5に示されたマウスの配列の5′から位置1603に 示されたヌクレオチドの配列を含むプロモーターを含んで成る、前記単離物。 5.核酸単離物であって、図2に示されている配列のプロモーターのフラグメ ントから本質的に成るプロモーターを含んで成る、前記単離物。 6.そのプロモーターがCANNTGモチーフを含むものである、請求項5に記載の 核酸単離物。 7.そのモチーフがCAGGTGである、請求項6に記載の核酸単離物。 8.そのプロモーターがTTCCGGモチーフを含むものである、請求項5〜7のい ずれか1項に記載の核酸単離物。 9.核酸単離物であって、図5に示されているマウスのプロモーターのフラグ メントから本質的に成る、プロモーターを含んで成る前記単離物。 10.そのプロモーターがCANNTGモチーフを含むものである、請求項9記載の核 酸単離物。 11.そのモチーフがCAGGTGである、請求項10に記載の核酸単離物。 12.そのプロモーターがTTCCGGモチーフを含むものである、請求項9〜11のい ずれか1項記載の核酸単離物。 13.核酸単離物であって、図2に示されたプロモーター配列の、1もしくは複 数のヌクレオチドの付加、挿入、欠失または置換による、アレレ、変異体または 誘導体であるヌクレオチドの配列から本質的に成るプロモーターを含んで成る、 前記単離物。 14.核酸単離物であって、図5に示されたマウスのプロモーター配列の、1も しくは複数のヌクレオチドの付加、挿入、欠失または置換による、アレレ、変異 体または誘導体であるヌクレオチドの配列から本質的に成るプロモーターを含ん で成る、前記単離物。 15.核酸構築体であって、異種配列に操作可能に結合した、請求項1〜14のい ずれか1項に記載の核酸のプロモーターを含んで成る前記構築体。 16.その異種配列がコード配列である、請求項15に記載の核酸構築体。 17.その異種配列がレポーター分子をコードするものである、請求項16に記載 の核酸構築体。 18.請求項15〜17のいずれか1項に記載の核酸構築体を含んで成る、宿主細胞 。 19.請求項18記載の宿主細胞をそのプロモーターからの前記異種配列の転写の ための条件下で培養することを含む方法。 20.請求項19記載の方法であって、その異種配列がコード配列であって、その 宿主細胞をコードされたペプチド産物またはポリペプチド産物の発現のための条 件下で培養する、前記方法。 21.請求項19または請求項20に記載の方法であって、その異種配 列またはコードされた産物の転写の検出を含んで成る、前記方法。 22.ウトロフィンプロモーターの活性を調節する物質の能力をスクリーニング する方法であって、請求項15〜17のいずれか1項に記載の核酸構築体を含有する 発現系を試験物質または候補物質と接触させ、その異種配列の転写またはコード されたペプチド産物もしくはポリペプチド産物の発現を測定することを含む、前 記方法。 23.その発現系が前記核酸構築体を含むものである、請求項19に記載の方法。 24.請求項22または請求項23に記載の方法によってウトロフィンプロモーター の活性を調節する能力を有する物質の同定に続いて、その物質の製造及び/また は組成物の製造もしくは調製におけるその物質の使用を含む方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9508236.8A GB9508236D0 (en) | 1995-04-24 | 1995-04-24 | Promoting gene expression |
GB9508236.8 | 1995-04-24 | ||
GB9526028.7 | 1995-12-20 | ||
GBGB9526028.7A GB9526028D0 (en) | 1995-04-24 | 1995-12-20 | Promoting gene expression |
PCT/GB1996/000979 WO1996034101A1 (en) | 1995-04-24 | 1996-04-24 | Utrophin gene promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11504515A true JPH11504515A (ja) | 1999-04-27 |
JP4364941B2 JP4364941B2 (ja) | 2009-11-18 |
Family
ID=26306918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53226196A Expired - Fee Related JP4364941B2 (ja) | 1995-04-24 | 1996-04-24 | ウトロフィン遺伝子プロモーター |
Country Status (7)
Country | Link |
---|---|
US (1) | US5972609A (ja) |
EP (1) | EP0824589B1 (ja) |
JP (1) | JP4364941B2 (ja) |
AT (1) | ATE256184T1 (ja) |
AU (1) | AU712450B2 (ja) |
DE (1) | DE69631041T2 (ja) |
WO (1) | WO1996034101A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090544A (en) * | 1995-07-26 | 2000-07-18 | Creative Biomolecules, Inc. | Methods and compositions for identifying morphogen analogs |
US7306903B1 (en) | 1995-07-26 | 2007-12-11 | Curis, Inc. | Methods and compositions for identifying morphogen analogs |
US6103491A (en) * | 1995-07-26 | 2000-08-15 | Creative Biomolecules, Inc. | Methods and compositions for identifying morphogen analogs |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6911307B1 (en) * | 1998-12-08 | 2005-06-28 | Proteus S.A. | Method of detection in vitro of a target substance in a sample comprising the labelling of said substance with a reporter gene and with the sequences necessary for the expression of said reporter gene in vitro |
GB9923423D0 (en) * | 1999-10-04 | 1999-12-08 | Isis Innovation | Promoting gene expression |
AU2002219070A1 (en) * | 2000-11-02 | 2002-05-15 | Myocontractag | Ets-transcription factor related compound specific promoter and transactivators thereof |
AU2008307643B9 (en) | 2007-09-28 | 2014-04-17 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
-
1996
- 1996-04-24 AT AT96911038T patent/ATE256184T1/de not_active IP Right Cessation
- 1996-04-24 EP EP96911038A patent/EP0824589B1/en not_active Expired - Lifetime
- 1996-04-24 DE DE69631041T patent/DE69631041T2/de not_active Expired - Lifetime
- 1996-04-24 JP JP53226196A patent/JP4364941B2/ja not_active Expired - Fee Related
- 1996-04-24 WO PCT/GB1996/000979 patent/WO1996034101A1/en active IP Right Grant
- 1996-04-24 AU AU54043/96A patent/AU712450B2/en not_active Ceased
- 1996-04-24 US US08/945,296 patent/US5972609A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE256184T1 (de) | 2003-12-15 |
US5972609A (en) | 1999-10-26 |
JP4364941B2 (ja) | 2009-11-18 |
WO1996034101A1 (en) | 1996-10-31 |
DE69631041D1 (de) | 2004-01-22 |
AU5404396A (en) | 1996-11-18 |
AU712450B2 (en) | 1999-11-04 |
DE69631041T2 (de) | 2004-09-02 |
EP0824589B1 (en) | 2003-12-10 |
EP0824589A1 (en) | 1998-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102606174B1 (ko) | 트리플 가이드 서열을 지닌 crispr/cas9를 사용한 엑손 스키핑 변형을 위한 최적화된 전략 | |
Zhu et al. | Promoter organization and activity of human monoamine oxidase (MAO) A and B genes | |
Cawthon et al. | A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations | |
Biggs et al. | A human Id-like helix-loop-helix protein expressed during early development. | |
Xu et al. | The neurofibromatosis type 1 gene encodes a protein related to GAP | |
Macklin et al. | Structure and expression of the mouse myelin proteolipid protein gene | |
McHUGH et al. | The Development Expression of the Rat α-Vascular and ϒ-Enteric Smooth Muscle Isoactins: Isolation and Characterization of a Rat ϒ-Enteric Actin cDNA | |
Iler et al. | A single homeodomain binding site restricts spatial expression of Wnt-1 in the developing brain | |
US20030032609A1 (en) | Methods of modulating of angiogenesis | |
US6524851B1 (en) | Hybrid nucleic acid molecules and vectors including β-globin regulatory elements | |
JP4364941B2 (ja) | ウトロフィン遺伝子プロモーター | |
Quirin-Stricker et al. | Transcriptional activation of human choline acetyltransferase by AP2-and NGF-induced factors | |
JP2002511749A (ja) | 9q32−33での腫瘍サプレッサー遺伝子DBCCR1 | |
JP2024506645A (ja) | 転写調節遺伝子の編集による疾患の治癒 | |
KR20230069157A (ko) | GJB2를 코딩하는 재조합 아데노 연관 바이러스 (rAAV) 및 그의 용도 | |
Ceccarini et al. | A splice variant of Dp71 lacking the syntrophin binding site is expressed in early stages of human neural development | |
AU783950B2 (en) | Utrophin gene promoter | |
US6087111A (en) | Utrophin gene promoter | |
US20020102552A1 (en) | Transcriptional regulation of the human beta3-adrenergic receptor gene | |
CA2216611C (en) | Utrophin gene promoter | |
Suzuki et al. | Structures and chromosome locations of the human MEF2A gene and a pseudogene MEF2AP | |
WO2022253340A1 (zh) | 环状RNA Circ-ACE2翻译的多肽及其应用 | |
Saitta et al. | Characterization of the human α1 (VI) collagen promoter and its comparison with human α2 (VI) promoters | |
US20030049697A1 (en) | Family of mechanosensitive human potassium channels activated by polyunsaturated fatty acids and their use | |
WO2002099117A2 (en) | Nucleic acid regulatory sequences and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060808 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070327 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090527 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090721 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090820 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120828 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |